Analysis of Investments
Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities
Medtronic PLC, adjustment to net income attributable to Medtronic
US$ in millions
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
An analysis of the net income figures from April 30, 2021, to April 24, 2026, reveals a period of volatility followed by a steady recovery trend. Net income experienced a significant peak in 2022 before contracting in 2023 and 2024, and subsequently trending upward through the 2026 projection.
- Reported Net Income Volatility
- Reported net income demonstrated a peak of 5,039 million US$ in 2022, followed by a contraction to 3,676 million US$ by 2024. A recovery is observed in the final two years of the period, with figures rising to 4,662 million US$ in 2025 and 4,801 million US$ in 2026.
- Analysis of Mark-to-Market Adjustments
- The divergence between reported and adjusted net income highlights the impact of mark-to-market valuations of available-for-sale securities. In 2022, reported net income was 301 million US$ higher than adjusted net income, indicating a substantial positive valuation gain. Conversely, in 2021, 2024, 2025, and 2026, adjusted net income exceeded reported figures, suggesting that reported earnings were negatively impacted by unrealized losses or downward mark-to-market adjustments.
- Trends in Adjustment Magnitude
- The magnitude of the adjustments fluctuated over the period. Following the significant positive impact in 2022, the variance narrowed in 2023. A recurring pattern emerges from 2024 to 2026, where reported net income remains consistently lower than adjusted net income, with the most pronounced gap occurring in 2025 at 149 million US$.
Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)
Medtronic PLC, adjusted profitability ratios
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
An analysis of profitability metrics from 2021 to 2026 reveals a cyclical trend characterized by a peak in 2022, a subsequent contraction during 2023 and 2024, and a recovery phase moving into 2025 and 2026. All primary ratios—net profit margin, return on equity (ROE), and return on assets (ROA)—demonstrate a strong positive correlation in their movement over the six-year period.
- Net Profit Margin Trends
- Reported net profit margins increased from 11.97% in 2021 to a peak of 15.90% in 2022, before declining to a period low of 11.36% in 2024. A recovery is observed in 2025 and 2026, with margins stabilizing between 13.20% and 13.90%. Adjusted net profit margins follow a nearly identical trajectory, though they remained slightly lower than reported figures during the 2022 peak and slightly higher during the 2024 trough, indicating that non-recurring adjustments had a stabilizing effect on core profitability.
- Return on Equity (ROE) Performance
- ROE exhibited significant volatility, with reported values rising from 7.01% in 2021 to 9.59% in 2022. After a decline to approximately 7.3% in 2023 and 2024, the ratio recovered to 9.71% in 2025 and remained constant through 2026. Adjusted ROE reached its highest point of 10.02% in 2025, suggesting that the underlying return on shareholder capital strengthened in the latter part of the period.
- Return on Assets (ROA) Analysis
- ROA trends mirror the other profitability ratios, peaking at 5.54% in 2022 and dropping to 4.09% in 2024. The ratio improved to 5.16% by 2026. The minimal variance between reported and adjusted ROA indicates that the impact of mark-to-market adjustments on available-for-sale securities was negligible relative to the total asset base and overall net income.
The consistent alignment between reported and adjusted ratios across all metrics suggests that the adjustments for mark-to-market securities and other non-operational items do not fundamentally alter the company's profitability profile. The data indicates a return to efficiency levels seen in 2022, with ROE and ROA stabilizing at higher levels by the end of the analyzed period.
Medtronic PLC, Profitability Ratios: Reported vs. Adjusted
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
2026 Calculations
1 Net profit margin = 100 × Net income attributable to Medtronic ÷ Net sales
= 100 × 4,801 ÷ 36,364 = 13.20%
2 Adjusted net profit margin = 100 × Adjusted net income attributable to Medtronic ÷ Net sales
= 100 × 4,849 ÷ 36,364 = 13.33%
The financial performance over the observed six-year period is characterized by significant volatility in both net income and profit margins, with a notable cycle of expansion, contraction, and subsequent recovery. A peak in profitability occurred in 2022, followed by a two-year decline, and a renewed upward trajectory starting in 2025.
- Adjusted Net Profit Margin Trends
- The adjusted net profit margin exhibited a fluctuating pattern, starting at 12.28% in 2021 and rising to a peak of 14.95% in 2022. This was followed by a sequential decline to 11.88% in 2023 and a low of 11.50% in 2024. A sharp recovery is evident in 2025, where the margin reached 14.35%, before moderating slightly to 13.33% in 2026.
- Net Income Analysis
- Adjusted net income followed a similar trajectory to the profit margins. After an initial increase from US$ 3,698 million in 2021 to US$ 4,738 million in 2022, income retracted to US$ 3,709 million in 2023 and remained relatively flat at US$ 3,722 million in 2024. The latter period saw a substantial increase, with adjusted net income climbing to US$ 4,811 million in 2025 and reaching US$ 4,849 million by 2026.
- Comparison of Reported and Adjusted Metrics
- A close correlation exists between reported and adjusted figures. In 2022, the reported net profit margin reached its highest point at 15.90%, outperforming the adjusted margin of 14.95%. Conversely, from 2023 through 2026, the reported and adjusted margins tracked closely, typically within a range of 0.1% to 0.7%. This suggests that the impact of non-recurring items or adjustments remained relatively stable and did not fundamentally alter the underlying profitability trend.
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
2026 Calculations
1 ROE = 100 × Net income attributable to Medtronic ÷ Shareholders’ equity
= 100 × 4,801 ÷ 49,463 = 9.71%
2 Adjusted ROE = 100 × Adjusted net income attributable to Medtronic ÷ Shareholders’ equity
= 100 × 4,849 ÷ 49,463 = 9.80%
The financial performance over the observed six-year period is characterized by a period of volatility followed by a recovery in profitability and equity returns. A notable peak in earnings occurred in 2022, followed by a contraction in 2023 and 2024, before returning to an upward trajectory in 2025 and 2026.
- Net Income Trends
- Adjusted net income exhibited significant fluctuation, rising from US$ 3,698 million in 2021 to a high of US$ 4,738 million in 2022. A subsequent decline was observed, with values dropping to US$ 3,709 million in 2023 and remaining relatively stagnant at US$ 3,722 million in 2024. A strong recovery followed, with adjusted net income increasing to US$ 4,811 million in 2025 and reaching US$ 4,849 million by 2026.
- Adjusted Return on Equity (ROE) Analysis
- The Adjusted ROE closely mirrored the trend of adjusted net income. After starting at 7.19% in 2021, the ratio rose to 9.02% in 2022. A contraction followed, bringing the ratio down to 7.20% in 2023 and 7.41% in 2024. The metric reached its peak in 2025 at 10.02%, before stabilizing slightly at 9.80% in 2026.
- Comparative Performance of Reported vs. Adjusted Metrics
- Reported and adjusted figures generally trended in tandem, though variances exist. In 2022, the reported ROE of 9.59% exceeded the adjusted ROE of 9.02%. However, by 2025, the adjusted ROE reached a higher peak of 10.02% compared to the reported ROE of 9.71%. This suggests that specific non-recurring items impacted the reported figures differently across the timeframe, but the underlying adjusted performance remained consistent with overall profitability shifts.
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2026-04-24), 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30).
2026 Calculations
1 ROA = 100 × Net income attributable to Medtronic ÷ Total assets
= 100 × 4,801 ÷ 93,028 = 5.16%
2 Adjusted ROA = 100 × Adjusted net income attributable to Medtronic ÷ Total assets
= 100 × 4,849 ÷ 93,028 = 5.21%
The financial performance over the analyzed period demonstrates a cyclical trend in both profitability and asset utilization efficiency. A pattern of growth, contraction, and subsequent recovery is evident, with performance peaking in 2022 and again toward the end of the forecast period in 2025 and 2026.
- Adjusted Net Income Analysis
- Adjusted net income exhibited significant volatility, rising from US$ 3,698 million in 2021 to US$ 4,738 million in 2022. A notable decline occurred in 2023, where income dropped to US$ 3,709 million, remaining relatively flat at US$ 3,722 million in 2024. A robust recovery is observed in the final two years, with figures climbing to US$ 4,811 million in 2025 and US$ 4,849 million in 2026.
- Adjusted Return on Assets (ROA) Trends
- The adjusted ROA closely tracks the trajectory of adjusted net income, indicating that fluctuations in earnings are the primary driver of asset efficiency. The ratio increased from 3.97% in 2021 to 5.21% in 2022, followed by a dip to 4.08% in 2023 and a slight marginal increase to 4.14% in 2024. Efficiency improved significantly in 2025, reaching a peak of 5.25%, before stabilizing at 5.21% in 2026.
- Comparative Analysis of Reported and Adjusted Metrics
- A high degree of correlation is observed between reported and adjusted figures. Reported ROA and adjusted ROA move in tandem, though reported ROA generally reflects slightly lower values during the recovery phase of 2025 and 2026. The narrow variance between reported and adjusted net income suggests that one-time adjustments have a minimal impact on the overarching trend of the company's asset productivity.